Tavio Capital’s Exact Sciences EXAS Stock Holding History

Tavio Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-34,329	Closed	-$2.98M	–	4
2020 Q2	$2.98M	Buy	+34,329	New	+$2.74M	3.96%	7

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Tavio Capital's EXAS Position: Q3 2020 in Review

Tavio Capital sold out of Exact Sciences (EXAS) in Q3 2020, closing a stake of 34,329 shares — an estimated $2.98M sold.

Tavio Capital first reported a position in EXAS in Q2 2020 and held it in 1 quarter. The position peaked at $2.98M in Q2 2020. 516 funds tracked by Wall St. Rank hold EXAS as of Q3 2020.

Tavio Capital reported no remaining Exact Sciences position as of Q3 2020 after selling out during the quarter.
Tavio Capital sold 34,329 Exact Sciences shares in Q3 2020, an estimated $2.98M.
Tavio Capital first reported a position in Exact Sciences in Q2 2020 and held it in 1 quarter.
Tavio Capital's Exact Sciences position peaked at $2.98M in Q2 2020.
516 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2020.

Based on Tavio Capital's 13F filing for Q3 2020.